Clinical trials: COPD Patients
COPD
Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep
Fluticasone (Advair), an inhaled corticosteroid and salmeterol, a long-acting beta agonist, are approved for use in the management of COPD.
- Trial name
- NCT00731770
- Testing
- Advair 250, Advair 250 - matched
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Milton S. Hershey Medical Center
Chronic Obstructive Pulmonary Disease
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04535986
- Testing
- Ensifentrine
- Where
- 122 sites in United States, Bulgaria and 10 more
- Volunteers
- 763 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
To demonstrate the non-inferiority of QVA149 110/50 µg o.d. to fluticasone/salmeterol 500/50 µg b.i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours 15 min and 23 hours 45 min post QVA149…
- Trial name
- NCT01709903
- Testing
- QVA149, Fluticasone/salmeterol
- Where
- 55 sites in Argentina, Chile and 2 more
- Volunteers
- 744 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.
- Trial name
- SPEED (NCT00542880)
- Testing
- Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg, Seretide Diskus (salmeterol/fluticasone) 50/500 μg
- Where
- 59 sites in Argentina, Australia and 7 more
- Volunteers
- 442 people
- Sponsor
- AstraZeneca
COPD, Asthma
Health Effects of Secondhand Smoke Exposure in Outdoor Smoking Areas in Patients With COPD and Asthma ( TackSHSWP5 )
Within the TackSHS project (H2020 project grant agreement No 681040), we will conduct a clinical research study, aiming at: i) to measure respiratory health effects when exposed to secondhand smoke (SHS) in patients with asthma…
- Conditions
- COPD, Asthma, Second Hand Tobacco Smoke
- Trial name
- TackSHSWP5 (NCT03074734)
- Testing
- Exposure to secondhand tobacco smoke
- Volunteers
- 60 people
- Sponsor
- Institut Català d'Oncologia
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One-Year Study
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00168844
- Testing
- Tiotropium Inhalation Solution
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Uphill Walking as Exercise for COPD Patients
This study is designed to provide preliminary information regarding how to improve pulmonary rehabilitation for persons with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04026529
- Testing
- walking on incline or walking at increasing speed
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the…
- Trial name
- NCT02371629
- Testing
- NVA237, Salbutamol
- Where
- 81 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 776 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
This study compared the efficacy of indacaterol versus placebo in COPD patients classified as GOLD 2014 Patient Group B. This was a 2-arm parallel group study that recruited COPD patients classified by GOLD Patient Gorup B.
- Trial name
- NCT02418468
- Testing
- Indacaterol
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
The purpose of this study is to evaluate the efficacy of this multicenter, randomized, double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study comparing 2 fixed dose combinations (FDCs) of…
- Trial name
- LAC-MD-27 (NCT01049360)
- Testing
- Aclidinium 400 μg / Formoterol 12 μg, Aclidinium 400 μg / Formoterol 6 μg, Aclidinium 400 μg
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
COPD
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual…
- Trial name
- AVANT (NCT03022097)
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination, Aclidinium bromide, Formoterol Fumarate
- Where
- 74 sites in China, India and 3 more
- Volunteers
- 1,625 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by…
- Trial name
- NCT04184297
- Testing
- Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
- Where
- United States
- Volunteers
- 27,190 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Cardiovascular Function in COPD Patients
The objectives of the study are to explore the effect of treatment with tiotropium + olodaterol fixed dose combination (FDC) compared to fluticasone propionate + salmeterol FDC on: reversal of left ventricular diastolic…
- Trial name
- NCT03055988
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 10 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
PT003 MDI Cardiovascular Safety Study
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
- Trial name
- NCT01349803
- Testing
- PT005 MDI, PT001 MDI, PT003 MDI
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 237 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD
Vector Engineering Clinical
This study aimed to validate a novel automatic non-invasive ventilation (NIV) mode that continuously adjusts expiratory positive airway pressure (EPAP) to the lowest value that abolishes tidal expiratory flow limitation (EFL).
- Trial name
- NCT04725500
- Testing
- Auto-Titrating EPAP
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Pulmonary Disease, Chronic Obstructive
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients…
- Trial name
- NCT00144339
- Testing
- tiotropium
- Where
- 490 sites in United States, Argentina and 35 more
- Volunteers
- 5,993 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients
To investigate the efficacy and safety of OPC-6535 in COPD patients, using the measurement of trough FEV1 over time as the primary endpoint.
- Trial name
- NCT00917150
- Testing
- tetomilast (OPC-6535)
- Where
- 9 sites in China, Japan and 1 more
- Volunteers
- 771 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Pulmonary Disease, Chronic Obstructive
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD.
- Trial name
- NCT00500318
- Testing
- Aclidinium Bromide
- Where
- 52 sites in United States, Canada
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Asthma
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.
- Trial name
- NCT01425801
- Testing
- LAS100977 0.313 μg, LAS100977 0.625 μg, LAS100977 1.25 μg
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare the systemic exposure to BI 1744 BS and tiotropium at steady state following inhalation of the fixed dose combination (FDC) of 10 μg BI 1744 CL plus 5 μg tiotropium bromide with the…
- Trial name
- NCT02231177
- Testing
- BI 1744 CL, BI 1744 CL/Tiotropium FDC, Tiotropium
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim